Research Synthesis: Semaglutide 2.4 mg Once Weekly Effects — full paper

Researka accepted publication: a180a3d8-5507-45cc-bde8-fb3c07f8c393 Source submission: ade507cb-3b3e-4c77-a95a-54c3b79ac825 Evidence-honesty note: 17/20 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on semaglutide intervention semaglutide 2 4 mg once weekly effects across 20 included source papers and 1320 high-confidence extracted claims. The evidence profile contains 3 direct clinical sources, 9 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 53 cross-study disagreements across the evidence base. Positive study-level signals are not the dominant direction in any outcome class; null signals are not the dominant direction in any outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic, contextual adjacent evidence, and safety and comorbidity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that semaglutide intervention semaglutide 2 4 mg once weekly effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.